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Abstract  
Background: There is a paucity of data on incidence, prevalence and mortality associated 
with non-CF bronchiectasis.  
Methods: Using Clinical Practice Research Datalink (CPRD) for participants registered 
between 1st January 2004 and 31st December 2013, we determined incidence, prevalence 
and mortality associated with bronchiectasis in the UK and investigated changes over time.  
Results: The incidence and point prevalence of bronchiectasis increased yearly during the 
study period. Across all age groups, the incidence in women increased from 21.2/100,000 
person-years in 2004 to 35.2/100,000 person-years in 2013, and in men from 18.2/100,000 
person-years in 2004 to 26.9/100,000 person-years in 2013. The point prevalence in women 
increased from 350.5/100,000 in 2004 to 566.1/100,000 in 2013 and in men from 
301.2/100,000 to 485.5/100,000 in 2013. Comparing morality rates in women and men with 
bronchiectasis in England and Wales (n=11,862) to mortality rates in the general population 
from ONS data, showed that in women the age adjusted mortality rate for the bronchiectasis 
population was 1437.7/100,000 and for the general population 635.9/100,000; (comparative 
mortality figure of 2.26). In men, the age adjusted mortality rate for the bronchiectasis 
population was 1914.6/100,000 and for the general population 895.2/100,000; (comparative 
mortality figure of 2.14).  
Conclusion: Bronchiectasis is surprisingly common and is increasing in incidence and 
prevalence in the UK, particularly in older age groups. Bronchiectasis is associated with a 
markedly increased mortality.  
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INTRODUCTION 
Bronchiectasis is a long term respiratory condition characterised by persistent airway 
infection and recurrent exacerbations in the presence of structurally abnormal bronchi. 
Although worldwide the commonest cause of bronchiectasis is previous acute lung infection, 
there is a large range of other causes and bronchiectasis could remain a relatively common 
condition even in high-income countries.  However, there are few recent, comprehensive 
data on the epidemiology and associated mortality of bronchiectasis in a high-income 
country. No large study has been performed in the UK since the 1950s and there are only 
limited relevant data from non-UK sources.[1-5] Bronchiectasis can co-exist and/or be 
associated with other long term respiratory conditions such as chronic obstructive pulmonary 
disease (COPD) and asthma, as well as many non-respiratory diseases including 
rheumatoid arthritis and HIV infection. Data on the co-existence of bronchiectasis with these 
diseases is lacking but is necessary to help inform management.  
 
Using primary care data (Clinical Practice Research Datalink (CPRD), we aimed to establish 
the incidence and prevalence of non-CF bronchiectasis in UK adults from 2004 to 2013. 
Additionally, we investigated the health care burden of bronchiectasis through mortality.  
 
METHODS 
Data sources 
CPRD is the world's largest validated computerized database of anonymized longitudinal 
medical records for primary care.[6,7] Data comprise approximately 14 million patients with 
around 5.4 million of these being currently alive and registered from 660 primary care 
practices spread throughout the UK. Records are derived from a widely used GP software 
system and contain complete prescribing and coded diagnostic and clinical information as 
well as information on tests requested, laboratory results and referrals made at or following 
on from each consultation.[8] The population of patients within CPRD have been shown to 
4 
 
be representative of the UK population with respect to age, gender and geographical 
distribution.[9]  
 
Study population to determine incidence and prevalence of bronchiectasis 
Incidence was determined within financial years, with individuals aged ≥18 years between 1st 
April 2004 and 31st March 2013 eligible for inclusion. To determine prevalence, the study 
population was the whole CPRD-HES linked population over the age of 18 enrolled in a 
CPRD practice on a specific date in each year between 2004 and 2013, stratified by age and 
gender.  
 
Bronchiectasis cohort study population and follow up time 
A dynamic cohort of individuals who were alive and contributing to linked CPRD at any time 
between 1st January 2004 and 31st December 2013 and who had a diagnosis of 
bronchiectasis were identified using pre-specified Read codes (on line supplement). We 
excluded individuals with co-existing Read codes for cystic fibrosis (CF) to reduce 
misclassification of CF as non-CF bronchiectasis, as well as anyone aged less than 18 years 
at time of diagnosis of bronchiectasis and people who only had a record of bronchiectasis 
posthumously.  Follow-up began at the latest of the study start date, patients’ 18th birthday, 
the date CPRD deemed the submitting general practice was ‘up to standard’ (i.e. the 
practice had passed a number of quality checks and deemed suitable for research use), the 
date a patient joined the practice + 365 days or at bronchiectasis diagnosis (for patients who 
received their first bronchiectasis code after start of the practice being up to standard on or 
after the 1st January 2004).  The additional 365 days was added to the date the patient 
joined the practice, in order to exclude retrospective recording of historical bronchiectasis 
diagnoses reported when visiting a new GP. [10] Follow-up ended at the earliest of the study 
end date, death, transfer out of the practice or the practices’ last data collection date. 
Patients who contributed at least one day of follow-up were included in the study. 
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Codes used to define variables of interest 
Information on demographic factors (age at study start, gender, ethnicity, and individual level 
socio-economic status), smoking status and other diseases associated with bronchiectasis 
(asthma, chronic obstructive pulmonary disease (COPD), Human Immunodeficiency Virus 
(HIV), rheumatoid arthritis, other connective tissue diseases, inflammatory bowel disease, 
bone marrow transplant, hypogammaglobulinaemia and allergic bronchopulmonary 
aspergillosis (ABPA)) were obtained from the CPRD data using Read codes.  Bronchiectasis 
was deemed to be idiopathic or post-infectious if it was not associated with any of the co-
morbidities listed above, and it was not possible within this database to further separate 
those two groups.  
 
Primary outcomes 
The outcome was incident or prevalent bronchiectasis, stratified by age, gender and year.   
 
Statistical Analyses 
Incidence and Point Prevalence 
Incidence rates were calculated by year, gender and age by dividing the number of new 
cases of bronchiectasis by the person time at risk. Point prevalence was calculated by 
dividing the number of currently registered patients active in the dataset who had a 
bronchiectasis diagnosis on or before a randomly selected date (16th February of each year 
(2004 to 2013)) by the total adult study population on that date. Age was grouped as those 
less than 30 years and then in ten-year age bands up to 80 years, then as ≥80 years.   
 
Cohort study 
The cohort of patients with prevalent bronchiectasis in the study period were used to 
estimate the prevalence of co-morbid illnesses potentially associated with bronchiectasis. 
The presence of these co-morbidities was ascertained both before and after the first 
bronchiectasis record.   
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Mortality rates 
We calculated crude all-cause mortality rates by gender and 10 year age bands in the 
bronchiectasis population in 2010 by calculating the number of deaths in people with 
bronchiectasis in the linked CPRD-HES dataset in 2010 and dividing this by the midpoint 
bronchiectasis population in 2010. We used CPRD-HES linked patients only in this analysis. 
We compared results to Office of National Statistics (ONS) published data on all-cause 
mortality figures for the same gender and age bands in England and Wales in 2010. 
Additionally, using direct standardisation, we calculated comparative mortality figures 
separately for men and women. [11,12] 
 
All statistical analyses were conducted using Stata version 13 (Texas).  
 
Ethics 
Ethics approval was obtained from ISAC (the Independent Scientific Advisory Committee 
overseeing CPRD (protocol 12_016)) and the LSHTM Ethics Committee. Following being 
granted ethics approval by ISAC, the length of the study was extended for a further two 
years (from end 2011 to 2013). This was considered a minor amendment and did not require 
further ISAC approval.  
 
RESULTS 
Incidence of bronchiectasis 
Across all age groups, the incidence of bronchiectasis in women increased overall from 
21.24 per 100,000 person-years in 2004 to 35.17 per 100,000 person-years in 2013, and in 
men from 18.19 per 100,000 person-years in 2004 to 26.92 per 100,000 person-years in 
2013. The details of age-specific rates are given in Table 1. The incidence of bronchiectasis 
in men and women in 2004 and in 2013 increased with increasing age, except in men in 
2013 in the ≥80 age group, and in women ≥80 in 2004 and 2013 in whom the incidence 
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decreased compared to the 70-79 year old age groups (table 1). The yearly incidence of 
bronchiectasis stratified by age and sex from 2004 to 2013 is shown in Figure 1.  
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Table 1: Incidence of bronchiectasis in 2004 and 2013 stratified by gender and age group (confidence intervals in brackets) 
Age Groups 
(years) 
Rate in men per 100,000 person-years 
                   2004                    2013 
Rate in women per 100,000 person-years 
2004                          2013 
Rate overall per 100,000 person-years 
2004                          2013 
18-29 2.44 (0.696, 8.56) 1.48 (0.296, 7.41) 1.54 (0.317, 7.47) 1.55 (0.321, 7.482) 2.01 (0.51, 8.01) 1.52 (0.31, 7.45) 
30-39 3.08 (1.01, 9.41) 4.14 (1.58, 10.85) 3.18 (1.06, 9.55) 5.36 (2.30, 12.50) 3.13 (1.03, 9.47) 4.75 (1.93, 11.68) 
40-49 7.74 (3.29, 15.66) 9.28 (4.88, 17.66) 8.95 (4.65, 17.23) 13.63 (8.02, 23.18) 8.34 (4.23, 16.44) 11.44 (6.41, 20.42) 
50-59 19.91 (12.83, 30.89) 26.36 (18.00, 38.61) 29.51 (20.57, 42.33) 35.96 (25.94, 49.86) 24.66 (16.62, 36.59) 31.13 (21.91, 44.24) 
60-69 49.68 (37.62, 65.60) 58.06 (44.90, 75.09 60.55 (47.07,77.89) 86.07 (69.69, 106.3) 55.17 (42.38, 71.82) 72.31 (57.43, 91.05) 
70-79 73.82 (58.77, 92.73) 126.66 (106.43,150.74) 66.32 (52.14, 84.36) 124.94 (104.86, 148.87) 69.72 (55.14, 88.16) 125.74 (105.59, 149.74) 
≥80 77.68 (62.20, 97.02) 117.47 (98.05, 140.74) 41.57 (30.68, 56.34) 97.85 (80.27, 119.28) 54.02 (41.38, 70.52) 105.38 (87.08, 127.54) 
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Prevalence of bronchiectasis 
Across all age groups, the point prevalence of bronchiectasis in women increased from 
350.5 per 100,000 in 2004 to 566.1 per 100,000 person-years in 2013, and in men from 
301.2 per 100,000 in 2004 to 485.5 per 100,000 in 2013. The details of prevalence by age 
are given in Table 2. The recorded prevalence of bronchiectasis increased over time within 
each age group in both men and women, remaining uncommon in the under 40s but 
reaching a very high prevalence in the elderly of around 1% by 2013. The exception was the 
50-59 year age group in whom the prevalence of bronchiectasis slowly declined for both 
men and women over time (Table 2 and Figure 2). The recorded prevalence of 
bronchiectasis was higher in men in increasing age groups in the later years of the study and 
in women for all age groups except in the over 80s (Figure 2).  
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Table 2: Prevalence of bronchiectasis in 2004 and 2013 stratified by gender and age group (confidence intervals in brackets) 
Age Groups 
(years) 
Prevalence in men per 100,000  
                    2004                               2013 
Prevalence in women per 100,000 
                     2004                              2013 
Prevalence Overall per 100,000 
                     2004                              2013 
18-30 28.8 (20.2, 33.3) 43.3 (32.2, 58.3) 29.7 (20.8, 42.5) 43.6 (32.4, 58.6) 29.3 (20.4,41.9) 43.4 (32.3,58.4) 
30-39 38.7 (28.3, 53.0) 58.2 (45.0, 75.2) 53.4 (40.8, 69.8) 79.3 (63.7, 98.8) 46.0 (34.5,61.4) 68.8 (54.3,87.0) 
40-49 85.2 (68.9, 105.3) 97.4 (79.9, 118.7) 110.7 (91.9, 133.3) 142.1 (120.6, 167.4) 98.0 (80.4,119.4) 119.8 (100.2,143.2) 
50-59 286.9 (255.6, 322.0) 224.0 (196.5, 255.3) 391.1 (354.3, 431.7) 285.9 (254.6, 321.0) 339.0 (304.8,377.0) 254.9 (225.5,288.2) 
60-69 477.4 (436.5, 522.1) 629.3 (582.1, 680.2) 638.4 (590.9, 689.7) 866.0 (810.4, 925.3) 557.9 (513.6,606.0) 747.7 (696.1,803.0) 
70-79 608.0 (561.7, 658.1) 1109.0 (1045.9, 1175.8) 698.1 (648.4, 751.6) 1370.3 (1300.1, 1444.2) 653.0 (605.0,704.9) 1239.7 (1172.9,1310.1) 
≥80 583.0 (537.7, 632.1) 1236.9 (1170.2, 1307.3) 532.3 (489.1, 579.3) 1175.6 (1110.6,1244.3) 557.7 (513.4,605.8) 1206.3 (1140.5,1275.8) 
 
11 
 
 
Bronchiectasis cohort study population 
The bronchiectasis diagnosed study population within CPRD consisted of 18,793 individuals. 
Over half the individuals (58.5%) were women, and the median age at diagnosis of adult 
bronchiectasis was 61.8 years (Interquartile range [IQR]: 47.5 to 72.2). Among patients for 
whom socioeconomic status information was available (64%), as measured by Index of 
Multiple Deprivation, more patients belonged to the higher IMD quintile and numbers 
decreased with decreasing IMD. Bronchiectasis was more common in patients with higher 
socioeconomic status as measured by Index of Multiple Deprivation (Table 3).  
 
Table 3: Baseline characteristics of the bronchiectasis study population  
Characteristic Category Entire study 
population 
(n=18,793) (%) 
Median age at 
diagnosis in years 
(IQR) 
 61.8 (47.5-72.2) 
   
Median length of time 
in the study in years 
(IQR)  
 7.2 (3.6-7.9) 
   
Gender Male 7798 (41.5) 
Female 10,995 (58.5) 
   
Smoking habit (ever, 
closest to diagnosis 
date) 
Never-smoker/not recorded 6003 (31.9) 
Ex-smoker 7118 (37.9) 
Current smoker 5672 (30.2) 
   
Index of multiple 
deprivation (IMD) 
1 (Least deprived) 3082 (16.4) 
 2 3013 (16.0) 
 3 2243 (11.9) 
 4 1935 (10.3) 
 5 (Most deprived) 1728 (9.2) 
 Unavailable 6792 (36.1) 
 
Co-existing co-morbidities 
11,914 (63.4%) people had at least one co-existing co-morbid illness associated with 
bronchiectasis. Asthma was the most prevalent co-existing co-morbid illness, followed by 
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COPD, then HIV infection, rheumatoid arthritis, and connective tissue disorders (Table 4). 
ABPA was only present in 1.8% of patients. Compared to those with co-morbid illnesses, 
patients with idiopathic or post-infectious bronchiectasis were slightly older at the time of 
diagnosis (62.7 years vs. 60.0; p<0.001).   
 
 
Table 4: Co-existing diagnoses associated with bronchiectasis. 
Co-existent illness Entire study 
population 
(n=18,793) 
(%*) 
Asthma 7988 (42.5) 
Chronic Obstructive 
Pulmonary Disease 
6774 (36.1) 
Human Immunodeficiency 
Virus 
1300 (6.9) 
Rheumatoid Arthritis 1163 (6.2) 
Other Connective tissue 
diseases 
969 (5.2) 
Inflammatory Bowel 
Disease 
527 (2.8) 
Bone Marrow Transplant 20 (0.11) 
Hypogammaglobulinaemia 172 (0.9) 
ABPA 339 (1.8) 
No co-morbidities above 6422 (34.2) 
*% add up to more than 100 as some patients had multiple co-morbidities 
 
Mortality rates 
Comparing age specific morality rates in men and women with bronchiectasis to age specific 
mortality rates calculated in the general population in England and Wales from ONS data, 
we found that in all age bands mortality rates were substantially higher in people with a 
diagnosis of bronchiectasis compared to the general population. The crude mortality rates by 
age group in 2010 per 1,000 population are given in Table 5.  Using direct standardisation, 
in women the age adjusted mortality rate for the bronchiectasis population was 1437.7 per 
100,000 and for the general population 635.9 per 100,000; (comparative mortality figure of 
2.26). In men, the age adjusted mortality rate for the bronchiectasis population was 1914.6 
per 100,000 and for the general population 895.2 per 100,000; (comparative mortality figure 
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of 2.14). This indicates that mortality for both men and women with bronchiectasis is more 
than twice the mortality in the general population, independent of age differences between 
the two populations. 
 
Table 5. Crude mortality rate by age group in 2010 per 1,000 population (95% CI). 
Rates have been calculated using mid-year population estimate for 2010. 
 
Age 
group 
Men                                                           Women 
  
 
General 
population 
Bronchiectasis 
cohort 
General 
population Bronchiectasis cohort 
18-49 1.3 (1.3-1.4) 13.1 (3.4-22.8) 0.8 (0.7-0.8) 6.4 (0.8-12.0) 
50-59 5.1 (5.0-5.2) 10.0 (2.6-17.3) 3.4 (3.4-3.5) 7.8 (2.4-13.2) 
60-69 12.5 (12.3-12.6) 29.5 (20.6-38.4) 7.9 (7.8-8.0) 16.0 (10.6-21.5) 
70-79 33.77 (33.4-33.9) 58.6 (46.4-70.7) 22.8 (22.6-23.0) 43.9 (34.9-52.8) 
80+ 111.8 (111.1-112.5) 144.6 (115.4-173.9) 98.9 (98.4-99.4) 160.1 (136.1-184.1) 
 
 
 
DISCUSSION 
This study provides detailed estimates of the recorded incidence and prevalence of 
bronchiectasis in the UK over time, the prevalence of associated diseases, and an 
assessment of the burden on healthcare resources in terms of mortality. Data from the USA, 
Germany and previously from the UK have all suggested that the clinical importance of 
bronchiectasis is increasing, with increases in prevalence [3,13], hospital admissions [4], and 
mortality.[5]  Our data provide additional insight beyond these papers, with the large number 
of patients included in the cohort and the long study period enabling us to give accurate 
estimates of bronchiectasis incidence and prevalence stratified by age groups and gender. 
Although general practices are self-selecting with regards to contributing to CPRD, they are 
broadly representative of the UK population,[9] and previous studies have established the 
validity of medical diagnoses [14,15] and prescribing records in CPRD. [16] Hence the 
cohort of patients included in our study is likely to be representative of patients with a 
diagnosis of bronchiectasis in their medical records across the UK. Overall this study 
provides important and previously unavailable information regarding bronchiectasis in the 
UK. The data are also likely to be representative for trends in other industrialised countries 
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and are in keeping with data form a previous British Thoracic Society Bronchiectasis audit. 
[23]  
 
The advent of antibiotics and improved standards of living in industrialised countries has led 
to large reductions in severe childhood respiratory tract infections, perhaps leading to an 
assumption that bronchiectasis was a disease of the past in these countries. However, we 
found that the recorded incidence and prevalence of bronchiectasis in the UK has increased 
year on year during the study period, with an increase in almost all age groups but with the 
most rapid increase seen in women over the age of 70 years. In the older population, 
bronchiectasis was a common disease affecting over 1% of both men and women aged over 
70.  Bronchiectasis was also surprisingly common in younger adults as well, with a 
prevalence in 2013 of over 40 per 100000 even in the under 30 year old population. The 
exception for the increasing prevalence of bronchiectasis in the UK over time is the 50-59 
year old group, for which prevalence slowly declined between 2004 and 2013. The reasons 
for this discrepancy are not clear – one potential explanation is that a proportion of 
bronchiectasis in the 50-59 age group is due to childhood disease that has become less 
common with time. In contrast, the increase in prevalence of bronchiectasis in older age 
groups is driven by adult-onset causes of bronchiectasis that are increasingly affecting older 
age groups. The reasons for the overall increased incidence and prevalence of 
bronchiectasis are not clear. It may be due to changes in the prevalence of causes of 
bronchiectasis, but also due to improved diagnosis rates with increased use of CT scans to 
assess patients with lung disease. It is also possible that changes in diagnostic labelling with 
respect to other associated respiratory diseases has contributed to the increased incidence. 
Comparing these data with published data available on other respiratory diseases, the 
prevalence of COPD has increased by 50% from 2000 to 2009 but incidence has remained 
static. [17] Overall, with bronchiectasis, the increased incidence and prevalence over time is 
likely to be at least partly driven by increased case ascertainment and increased 
investigation of the elderly population. Nonetheless, age specific mortality rates were higher 
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in people with bronchiectasis than the general population (including in younger patients), 
indicating that a diagnosis of bronchiectasis is associated with important health effects. 
Whether the increased mortality in the bronchiectasis cohort is due to complications from co-
existing illnesses or directly attributable to bronchiectasis is not known. We were only able to 
investigate all cause mortality. It is not clear from these data whether the increased mortality 
in people with bronchiectasis was due to non-respiratory causes, or indeed whether mortality 
was higher in those with co-morbidities.  More studies are needed to characterise the health 
burden associated with bronchiectasis by investigating GP visits for exacerbations and 
hospital admissions, and to investigate the mechanisms of the increased mortality of patients 
with bronchiectasis.  
 
Bronchiectasis has a significant sex bias, being more common in women than in men. 
Bronchiectasis has a wide range of causes and associated co-morbidities. These include 
both asthma and irreversible airways obstruction, which given the spirometric criteria used to 
diagnose COPD in the UK could be misdiagnosed as COPD.  Conversely, bronchiectasis is 
increasingly recognised as a complication of asthma and COPD. [18-20] In our cohort of 
patients with bronchiectasis, both asthma and COPD were very common, associated with 
43% and 36% of subjects respectively. It is unclear in what proportion of these patients the 
diagnosis of bronchiectasis was secondary to the airways disease rather than the primary 
disease. One interesting finding was the fact that asthma associated bronchiectasis was 
more common than COPD associated bronchiectasis. While some of this may be due to 
misclassification of COPD as asthma in the database, it warrants further investigation. The 
low prevalence of ABPA associated bronchiectasis in this cohort is likely due to under 
recording of ABPA in primary care.  One new and unexpected finding was the relatively high 
proportion of patients with bronchiectasis who were HIV positive (6.9%), had rheumatoid 
arthritis or another connective tissue disease (11.4%), or IBD (2.8%). Although these 
conditions are known causes of bronchiectasis, they were not prominent contributors in 
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previous case series of bronchiectasis associations from secondary or tertiary referral 
centres.[21] According to national figures, the estimated prevalence of HIV is around 1.5 per 
1000 of the UK population. [22] The increase in the association of HIV infection, rheumatoid 
arthritis / connective tissue disease, and inflammatory bowel disease with bronchiectasis in 
our cohort may reflect the strength of population studies for establishing more accurate 
information on disease associations. We believe that the CPRD population is representative 
and not richer in HIV than expected, it is likely that more CTs are done in the HIV population 
and so the rate of bronchiectasis is higher in this group. This may mean that the rate of 
bronchiectasis in this group is actually more accurate than in the non-HIV group. 
 
Limitations 
In order to improve sensitivity and specificity of the diagnosis only a small number of specific 
Read codes were used to identify subjects with bronchiectasis, and individuals had to be 
over 18 years of age when they were first diagnosed.  As a consequence, some patients 
with bronchiectasis would have been excluded. Bronchiectasis was deemed to be idiopathic 
if it was not associated with any of the co-morbidities previously listed. While some of the 
bronchiectasis codes could be post infectious, we included individuals with such codes in the 
idiopathic bronchiectasis group as these codes were only used in 2% of our study population 
and over half of those patients also had a Read code for “Bronchiectasis” (see appendix). 
We are unable to confirm that the diagnosis of bronchiectasis in the GP records is accurate. 
We did not have access to CT scan data and therefore cannot be sure that that in each 
recorded case of bronchiectasis the diagnosis was attained according to current guidelines. 
However, as the diagnosis is usually made in a secondary care setting and requires a CT 
scan,[23,24] it is unlikely that a diagnosis of bronchiectasis will be recorded by the GP 
without confirmation from secondary care.   
 
Conclusions and clinical implications 
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There are major deficits in our understanding of the pathophysiology and management of 
bronchiectasis,[25] yet our data show that bronchiectasis is increasingly common and is 
associated with a substantially raised mortality. Bronchiectasis remains an important cause 
of respiratory disease in the UK and this should be reflected in the provision of clinical care 
for these patients.  
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Figure 1: Incidence of bronchiectasis in the UK from 2004 to 2013 stratified by age in a) 
men and b) women  
Figure 2: Prevalence of bronchiectasis in the UK from 2004 to 2013 stratified by age in a) 
men and b) women  
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